

Malignant Peripheral Nerve Sheath Tumor Arising in a Neurofibroma

MONICA KUMBHAT M*, LEENA DENNIS JOSEPH†, ARCHANA B*, ARULAPPAN‡

ABSTRACT

Malignant peripheral nerve sheath tumor (MPNST) is a rare variety of soft tissue sarcoma of ectomesenchymal origin. These tumors present diagnostic difficulties in differentiating from other high-grade spindle sarcomas. This is a case of a 45-year-old lady who presented with pain and swelling in the groin for past 4 months, which on excision and histopathology revealed an MPNST in a neurofibroma.

Keywords: Malignant peripheral nerve sheath tumor, soft tissue sarcoma, ectomesenchymal, neurofibroma

Malignant peripheral nerve sheath tumor (MPNST) is a malignant neurogenic tumor that occurs with high frequency (8-13%) in association with neurofibromatosis type 1 (NF-1), arising either *de novo* or in transition from neurofibroma.¹ It either develops from peripheral nerves, pre-existing benign neurofibromas or schwann cells. NF-1 patients are more frequently diagnosed with MPNST in the third or fourth decades of life, whereas the sporadic form of MPNST is most frequently diagnosed in the sixth or seventh decades of life.

CASE REPORT

A 45-year-old female developed pricking type of pain in the right groin extending to right knee for a duration of 4 months. There was also a history of fever on and off for 1 month. She gave a history of neurofibromatosis for 35 years. On local examination, a large neurofibroma was seen in the right inguinal region. Neurofibromas were also seen in the knee and arms (Figs. 1 and 2).

On ultrasound, there was a well-defined heterogeneous mass involving predominantly deep subcutaneous and muscular planes of proximal right thigh measuring 9.7 × 5.7 × 5.8 cm. Fine needle aspiration cytology (FNAC) of the same lesion showed fibrocytes, mature adipocytes, a few spindle-shaped cells with sharp ends suggestive of wavy nerve fibers. She had history of excision of the swelling in the same region 2 years ago, which was histologically proved to be a neurofibroma.

In the same region, the patient presented with the present swelling. On excision of the mass, histologically it showed an undifferentiated pleomorphic sarcoma (Fig. 3), which was confirmed on immunohistochemistry



Figure 1. Single, small neurofibroma seen on lateral aspect of the left knee.

*Postgraduate Student

†Professor

Dept. of Pathology

‡Professor

Dept. of General Surgery

Sri Ramachandra Medical College, Chennai, Tamil Nadu

Address for correspondence

Dr Leena Dennis Joseph

Professor

Dept. of Pathology

Sri Ramachandra University, Porur, Chennai - 600 116, Tamil Nadu

E-mail: leenadj@gmail.com



Figure 2. Both arms showing multiple neurofibromas of varying sizes.




Figure 3. Pleomorphic tumor cells with mitotic figures (H&E x400).




Figure 4. S-100 positivity in the tumor cells (IHC x100).

to be positive for vimentin and S-100 (Fig. 4) suggesting a neural origin. The tumor cells were markedly pleomorphic with increased mitosis, many of them being atypical. Thus, a diagnosis of MPNST in a neurofibroma was given. Patient was referred to a radiation oncologist for further management.

DISCUSSION

MPNST is a rare malignant tumor with poor prognosis accounting for 3-10% of all soft tissue sarcomas. It is the second most common variety of soft tissue sarcomas seen. A combination of gross and microscopic findings along with immunohistochemical studies is commonly used to diagnose a case of MPNST.

These tumors occur in equal frequency in males and females and some series have shown a female preponderance. The majority of these tumors are seen involving the extremities; although tumor were also seen in unusual sites, such as the pelvis, retroperitoneum and infratemporal fossa. Imaging is routinely performed to assess the extent of the disease and plan surgical resection. However, it does not reliably determine the malignant transformation from neurofibroma to MPNST. Magnetic resonance imaging (MRI) is the investigation of choice because it can reveal the nerve of origin. Grossly, the tumor size ranges from 4 to 24 cm in greatest dimension.²

Histologically, following criteria are used for the diagnosis of MPNST: a) Gross fusiform tumors in relation to nerves; b) microscopic feature of spindle cell with fascicular pattern and varying degrees of mitosis, necrosis and tumor calcification; c) presence of associated benign neurofibroma or schwannian cells and d) positive immunohistochemical staining for S-100 protein, neuron-specific enolase and others like actin, cytokeratin, smooth muscle actin and vimentin to differentiate from other spindle cell sarcomas. The tumors are classified as low-grade and high-grade on the basis of their cellular differentiation, mitotic count, tumor necrosis and expression of MIB-1 proliferation marker.³

However, it is not always possible to demonstrate the origin from a nerve, especially when it arises from a small peripheral branch. This point was exemplified in a series by Nambisan et al,⁴ in which nerves could not be identified in 61% of cases of MPNST and in another series, in which nerve origin could be identified only in 45-56% cases. Still, there are several other distinct features, such as proliferation of tumor in the subendothelial zones of vessels with neoplastic cells

herniating into vessel lumen and proliferation of small vessels in the walls of the large vessels, which are very characteristic features of MPNST. Syndromes that are associated with MPNST are NF-1 and NF-2.

Histologically, strict morphologic criteria must be applied to distinguish the spectrums of MPNSTs from cellular schwannoma, atypical and malignant meningioma and from a variety of rarely occurring intracranial sarcomas, such as high-grade pleomorphic sarcoma "malignant fibrous histiocytoma" fibrosarcoma, synovial sarcoma and leiomyosarcoma. On the benign side of the spectrum, cellular schwannoma is another tumor to be distinguished from MPNST. This tumor is particularly prone to be mistaken for malignancy, given the presence of hypercellularity, mitotic activity, and occasional locally aggressive growth. Strong S-100 protein as well as collagen IV/laminin immunoreactivity is the rule in this tumor. With respect to separating MPNST from benign nerve sheath tumors, p53 may be useful, strong immunostaining being seen in the majority of MPNSTs.⁵ Ten percent of MPNSTs exhibit focal divergent differentiation, either mesenchymal (rhabdomyosarcoma, chondrosarcoma, osteosarcoma, angiosarcoma) or epithelial (mucin-producing, neuroendocrine or squamous type).

CONCLUSION

MPNSTs are aggressive, high-grade, therapy-resistant and associated with poor prognosis. A combination of clinical, pathological and immunohistochemistry helps in diagnosing these tumors. Proliferation marker (MIB-1) can be a good adjunct to grade and tailor the

treatment in MPNST. Sex and cellular differentiation are the new adverse prognostic factors for survival of the patients. Postoperative radiotherapy has a definitive role in both disease free and overall survival. Though multimodality therapy, including surgical resection and adjuvant radiotherapy, is available, the prognosis remains dismal. Modern clinical studies and the development of effective targeted chemotherapy are needed to gain control of the disease.

REFERENCES

1. Sun D, Tainsky MA, Haddad R. Oncogene Mutation Survey in MPNST cell lines enhances the dominant role of hyperactive Ras in NF1 associated pro-survival and malignancy. *Transl Oncogenomics*. 2012;5:1-7.
2. Kar M, Deo SV, Shukla NK, Malik A, DattaGupta S, Mohanti BK, et al. Malignant peripheral nerve sheath tumors (MPNST) - clinicopathological study and treatment outcome of twenty-four cases. *World J Surg Oncol*. 2006;4:55.
3. Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. *Int J Cancer*. 1984;33(1):37-42.
4. Nambisan RN, Rao U, Moore R, Karakousis CP. Malignant soft tissue tumors of nerve sheath origin. *J Surg Oncol*. 1984;25(4):268-72.
5. Scheithauer BW, Erdogan S, Rodriguez FJ, Burger PC, Woodruff JM, Kros JM, et al. Malignant peripheral nerve sheath tumors of cranial nerves and intracranial contents: a clinicopathologic study of 17 cases. *Am J Surg Pathol*. 2009;33(3):325-38.



Positive Effects of Meditation Seen on Brain Imaging

Reductions in perceived stress and anxiety after transcendental meditation (TM) have been associated with functional changes in key regions of the brain, reported the first study investigating the effects of the practice on the brain with the help of resting-state functional magnetic resonance imaging (fMRI).

Meditators had lower levels of anxiety and stress following TM practice for 3 months, and the changes in perceived psychological well-being were tied to modifications in brain functional connectivity, reported researchers in the journal *Brain and Cognition*.

Smoking and Drinking Linked to Recreational Drug Use by Young People

The use of alcohol and tobacco by young people and children is associated with the use of illicit drugs, stated a UN-backed narcotics control body.

The International Narcotics Control Board (INCB) annual report mentioned studies that suggested that in young people 16-19 years of age, early use of alcohol, tobacco and cannabis leads to higher odds of the use of opiates and cocaine in adulthood... (UN)

Empower Diabetes Patient

GLYCIPHAGE®

Metformin 250 mg Tablets, 500 mg & 850 mg Press Tablets

GLYCIPHAGE SR®

Metformin 500 mg, 850 mg & 1000 mg Sustained Release Tablets



GLYPTEN

Teneligliptin 20 mg

GLYCIPHAGE®-VG

Metformin SR 500 mg + Voglibose 0.2 mg + Glimepiride 1 mg / 2 mg Tablets



GLYPTEN™ - M

Teneligliptin 20 mg and Metformin Hydrochloride 500 mg SR Tablets

GLYCIPHAGE®-G ^{1mg}/_{2mg}

Metformin SR 500 mg + Glimepiride 1 mg / 2 mg

GLYCIPHAGE®-G ^{1mg}/_{2mg} FORTE

Metformin SR 1000 mg + Glimepiride 1 mg / 2 mg

Voliphage™ ^{0.2 mg}/_{0.3 mg}

Voglibose 0.2 mg / 0.3 mg Tablets

Voliphage™-M ^{0.2 mg}/_{0.3 mg}

Metformin SR 500 mg + Voglibose 0.2 mg / 0.3 mg Tablets

FOXSTAT™

Febuxostat 40 mg / 80 mg Tablets

DIAVIT™ PLUS

POZITIV®

Pioglitazone Hydrochloride 7.5 mg, 15 mg Tablets

POZITIV-G™ ^{1mg}/_{2mg}

Pioglitazone 15 mg + Glimepiride 1 mg/2mg Tablets

BENALGIS®

Benfotiamine 100 mg Tablets

PRENEUROLIN™ PLUS

Pregabalin 75 mg and Mecobalamin 750 mcg Capsules



DIABÉTIX

A Division of
**FRANCO-INDIAN
PHARMACEUTICALS PVT. LTD.**